Topic · Melanoma and MAPK Pathways
Most cited papers in Melanoma and MAPK Pathways
What are the most cited papers in Melanoma and MAPK Pathways?
The most cited paper in Melanoma and MAPK Pathways is "Mutations of the BRAF gene in human cancer" (Helen Ruth Davies et al., 2002), with 10,791 citations. Next come "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" (8,623) and "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma" (8,266).
Showing 50 of 99 papers. Every paper with more than 1,697 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Mutations of the BRAF gene in human cancer Helen Ruth Davies et al. · Nature | Jun 2002 | 10,791 |
| 2 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Jordi Barretina et al. · Nature | 27 Mar 2012 | 8,623 |
| 3 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin et al. · New England Journal of Medicine | 31 May 2015 | 8,266 |
| 4 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine | 5 Jun 2011 | 7,801 |
| 5 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine | 19 Apr 2015 | 5,968 |
| 6 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine | 11 Sep 2017 | 5,453 |
| 7 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 5,431 |
| 8 | Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis Zhengui Xia, Martin Dickens, Joël Raingeaud et al. · Science | 24 Nov 1995 | 5,341 |
| 9 | Mammalian MAP kinase signalling cascades Lufen Chang, Michael Karin · Nature | Mar 2001 | 5,148 |
| 10 | Cancer drug resistance: an evolving paradigm Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley et al. · Nature reviews. Cancer | 24 Sep 2013 | 4,739 |
| 11 | Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation C. J. Marshall · Cell | 1995 | 4,623 |
| 12 | Final Version of 2009 AJCC Melanoma Staging and Classification Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology | 16 Nov 2009 | 4,621 |
| 13 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert et al. · New England Journal of Medicine | 5 Jun 2011 | 4,523 |
| 14 | Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases Gary L. Johnson, Razvan Lapadat · Science | 5 Dec 2002 | 4,334 |
| 15 | Signal Transduction by the JNK Group of MAP Kinases Roger J Davis · Cell | Oct 2000 | 4,242 |
| 16 | BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Scott M. Wilhelm et al. · Cancer Research | Oct 2004 | 4,060 |
| 17 | Specificity and mechanism of action of some commonly used protein kinase inhibitors Stephen Davies, Helen Reddy, Matilde Caivano et al. · Biochemical Journal | Oct 2000 | 4,060 |
| 18 | Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions* Gray W. Pearson, Fred L. Robinson, Tara Beers Gibson et al. · Endocrine Reviews | Apr 2001 | 4,053 |
| 19 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin et al. · New England Journal of Medicine | 28 Sep 2019 | 3,784 |
| 20 | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Willy Hugo, Jesse Meir Zaretsky, Lu Sun et al. · Cell | Mar 2016 | 3,611 |
| 21 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Keith T. Flaherty, Igor J. Puzanov, Kevin B. Kim et al. · New England Journal of Medicine | 25 Aug 2010 | 3,581 |
| 22 | PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo Dario R. Alessi, Ana Cuenda, Philip Cohen et al. · Journal of Biological Chemistry | Nov 1995 | 3,433 |
| 23 | The MAPK signaling cascade Rony Seger, Edwin G. Krebs · The FASEB Journal | Jun 1995 | 3,408 |
| 24 | Mammalian Mitogen-Activated Protein Kinase Signal Transduction Pathways Activated by Stress and Inflammation John M. Kyriakis, Joseph Avruch · Physiological Reviews | Apr 2001 | 3,398 |
| 25 | A central role for JNK in obesity and insulin resistance Jiro Hirosumi, Gürol Tuncman, Lufen Chang et al. · Nature | 21 Nov 2002 | 3,377 |
| 26 | Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases Marie Cargnello, Philippe P. Roux · Microbiology and Molecular Biology Reviews | Mar 2011 | 3,321 |
| 27 | Genomic Classification of Cutaneous Melanoma Rehan Akbani et al. · Cell | Jun 2015 | 3,302 |
| 28 | Targeting RAS signalling pathways in cancer therapy Julian Downward · Nature reviews. Cancer | 2003 | 3,287 |
| 29 | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse Meir Zaretsky et al. · New England Journal of Medicine | 13 Jul 2016 | 3,284 |
| 30 | JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain Benoit Dérijard, Masahiko Hibi, I‐Huan Wu et al. · Cell | Mar 1994 | 3,222 |
| 31 | MAP kinase signalling pathways in cancer Amardeep S. Dhillon, Suzanne Hagan, Oliver Rath et al. · Oncogene | 14 May 2007 | 3,062 |
| 32 | Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase Margaret F. Favata, Kurumi Y. Horiuchi, Elizabeth J. Manos et al. · Journal of Biological Chemistry | Jul 1998 | 3,045 |
| 33 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild et al. · The Lancet | 25 Jun 2012 | 3,009 |
| 34 | AP-1 as a regulator of cell life and death Eitan Shaulian, Michael Karin · Nature Cell Biology | May 2002 | 2,999 |
| 35 | MAPK signal pathways in the regulation of cell proliferation in mammalian cells Wei Zhang, Hui-Tu Liu · Cell Research | Mar 2002 | 2,941 |
| 36 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al. · The Lancet | 21 Nov 2012 | 2,934 |
| 37 | Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF Paul Wan, Mathew J. Garnett, Stephen Mark Roe et al. · Cell | Mar 2004 | 2,841 |
| 38 | Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty et al. · New England Journal of Medicine | 30 Sep 2012 | 2,838 |
| 39 | Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine | 21 Feb 2018 | 2,827 |
| 40 | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Patrick J. Roberts, Channing J. Der · Oncogene | 14 May 2007 | 2,821 |
| 41 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael Andrew Postow et al. · New England Journal of Medicine | 20 Apr 2015 | 2,804 |
| 42 | Mitogen-Activated Protein Kinase: Conservation of a Three-Kinase Module From Yeast to Human Christian A. Widmann, Spencer Bruce Gibson, Matthew B. Jarpe et al. · Physiological Reviews | 1999 | 2,765 |
| 43 | Oncogenes and signal transduction Lewis C. Cantley, Kurt R. Auger, Christopher F Carpenter et al. · Cell | 1991 | 2,762 |
| 44 | Distinct Sets of Genetic Alterations in Melanoma John A. Curtin, Jane Fridlyand, Toshiro Kageshita et al. · New England Journal of Medicine | 16 Nov 2005 | 2,732 |
| 45 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 2,718 |
| 46 | A synthetic inhibitor of the mitogen-activated protein kinase cascade. David T. Dudley, Long Pang, Stuart J. Decker et al. · Proceedings of the National Academy of Sciences | 15 Aug 1995 | 2,717 |
| 47 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber et al. · The Lancet Oncology | 23 Mar 2015 | 2,696 |
| 48 | A Landscape of Driver Mutations in Melanoma Eran Hodis et al. · Cell | Jul 2012 | 2,672 |
| 49 | Signal integration by JNK and p38 MAPK pathways in cancer development Erwin Friedrich Wagner, Ángel R. Nebreda · Nature reviews. Cancer | 24 Jul 2009 | 2,672 |
| 50 | A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells Jiahuai Han, Jeffrey D. Lee, L. Bibbs et al. · Science | 5 Aug 1994 | 2,670 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.